Cardiome Oxyprim, Chronic Gout Drug Trials May Use Surrogate Endpoints For Approval, Cmte. Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Surrogate endpoint should seek a reduction in serum uric acid to a level of 6 mg/dL. Clinical outcome trials to confirm benefits of chronic gout products through reduction in gouty attacks should be carried out post-approval.
You may also be interested in...
With Zurampic, FDA Again Made Do With Sorry State Of Regulatory Science In Gout
Zurampic, which AstraZeneca licensed to Ironwood, pushed the limits of FDA's tolerance of the regulatory compromises agency has had to make in gout; our Drug Review Profile shows how statistician's case against approval received serious consideration, although the agency ultimately valued consistency with previous approvals in the space.
Cardiome Oxyprim “Approvable” For Gout, But Product’s Future Now In Doubt
FDA requests additional clinical and manufacturing data. Cardiome will “reflect” on FDA’s comments before making a final decision on oxypurinol.
Cardiome Oxyprim “Approvable” For Gout, But Product’s Future Now In Doubt
FDA requests additional clinical and manufacturing data. Cardiome will “reflect” on FDA’s comments before making a final decision on oxypurinol.